Quinagolide - Ferring Pharmaceuticals/Novartis
Alternative Names: CV 205 502; FE-999051; Norprolac; Quinagolide hydrochloride; SDS-205502; SDZ-205502Latest Information Update: 10 Oct 2022
At a glance
- Originator Novartis
- Developer Ferring Pharmaceuticals; Novartis
- Class Aminoquinolines; Analgesics; Infertility therapies; Small molecules
- Mechanism of Action Dopamine D2 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Female infertility; Hyperprolactinaemia; Prolactinoma
- Phase II Adenomyosis; Endometriosis; Pain
Most Recent Events
- 18 Jul 2021 Ferring Pharmaceuticals completes the phase II QLARITY trial for Endometriosis and Adenomyosis in Italy, Germany, Denmark and Poland (Vaginal) (NCT03749109)
- 17 Sep 2020 Ferring Pharmaceuticals re-initiates enrolment in the phase II RQUEL trial for Pain in USA (Vaginal) (NCT03692403)
- 12 Jun 2020 Ferring Pharmaceuticals re-initiates recruitment in the phase II QLARITY trial for Adenomyosis in Italy, Denmark, Poland and Germany (NCT03749109)